pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Aug 21·1 min read
save

Cure for HIV must protect long-term survivors from loss of benefits

Aug 21, 2026·read at STAT ↗Neutral

The authors, a postdoctoral researcher, a long‑term HIV survivor, and the head of a survivor alliance, argue that a future HIV cure should not jeopardize the support systems that have kept many patients alive.

They warn that without clear policy safeguards, a cure-or even durable viral control-could be interpreted as a reason to end benefits and services for long‑term survivors, creating a “benefits cliff.”

The piece calls on policymakers to anticipate these issues now, ensuring that medical breakthroughs are paired with protections for those who have depended on existing assistance.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: A cure for HIV would be a triumph. But it shouldn’t harm survivors”

read at STAT ↗
1,342 words · retrieved Aug 21
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
University of Pennsylvania2Ultragenyx Pharmaceutical Inc.
topics
Nephrology2CardiologyDuchenne Muscular DystrophyOncologyRare Disease

related stories

  • Jul 30New funding, new jobs: 4 biotechs hiring after series B raisesBioSpace
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Dec 22Fierce Biotech Fundraising Tracker '26: TriGemX tacks on $94M; AnaCardio adds $71MFierce Biotech
  • 3h agoFoghorn cuts 40% of workforceBioSpace
  • Sep 24Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugsFierce Biotech